Skip to main content

Gossamer Bio Inc

For the period ended Mar 31, 2024. Filed May 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

GOSS$11.28+6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and par value amounts)

March 31, 2024December 31, 2023
ASSETS · (unaudited)
Current assets
Cash and cash equivalents$38,863$32,109
Marketable securities205,531264,316
Prepaid expenses and other current assets10,87510,094
Total current assets255,269306,519
Property and equipment, net1,0741,648
Operating lease right-of-use assets2,4043,131
Other assets613618
Total assets$259,360$311,916
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable$2,660$5,526
Accrued research and development expenses8,9297,779
Current portion of long-term debt9,58911,613
Accrued expenses and other current liabilities14,64126,680
Total current liabilities35,81951,598
Long-term convertible senior notes196,819196,591
Long-term debt—814
Operating lease liabilities - long-term—144
Total liabilities232,638249,147
Commitments and contingencies (Note 9)
Stockholders' equity
Common stock, $0.0001 par value; 700,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 226,218,653 shares issued and outstanding as of March 31, 2024, and 225,409,315 shares issued and outstanding as of December 31, 20232323
Additional paid-in capital1,281,2951,275,136
Accumulated deficit(1,253,968)(1,212,040)
Accumulated other comprehensive loss(628)(350)
Total stockholders' equity26,72262,769
Total liabilities and stockholders' equity$259,360$311,916
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.